Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crohn's disease
Pharma
BMS' Zeposia comes up short in Crohn's disease study
Interim analysis of Bristol Myers Squibb’s 12-week induction trial of Zeposia in Crohn’s disease has failed to achieve its primary endpoint.
Kevin Dunleavy
Mar 29, 2024 8:15am
Takeda’s Alofisel flunks phase 3 trial in Crohn's complication
Oct 19, 2023 8:43am
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara
Oct 16, 2023 10:07am
Lilly's mirikizumab delivers Crohn's win after FDA rejection
Oct 12, 2023 11:21am
FDA signs off on Takeda's subcutaneous version of Entyvio
Sep 28, 2023 11:32am
AbbVie's Skyrizi deals blow to J&J's Stelara in IBD trial
Sep 12, 2023 11:26am